GIP Investment to Fuel mPharma’s Expansion in West Africa’s Healthcare Market
Growth Investment Partners (GIP) Ghana Ltd has announced a strategic investment in mPharma Ghana Ltd to support the expansion of affordable primary healthcare and pharmaceutical access across Ghana and Francophone West Africa.
The investment, backed by British International Investment (BII), is expected to help mPharma optimise medicine inventory in its existing mutti pharmacy network, strengthen operations in Ghana, and accelerate the rollout of its QualityRx franchise model in Togo and Benin. The move is part of mPharma’s broader growth strategy in Francophone West Africa, a region where demand for regulated, affordable healthcare services continues to rise.
Expanding Affordable Healthcare
Founded in 2013, mPharma operates a technology-enabled network of community pharmacies and telehealth services designed to reduce medicine costs and improve access to licensed doctors. Its mutti pharmacy franchise model converts independent pharmacies into certified primary care points, providing branded services, supply chain support and digital health management tools.
The company’s impact has grown steadily, with its mutti membership programme expanding from fewer than 10,000 subscribers in 2019 to more than 400,000 across Africa by the end of 2024. More than 70 percent of patients report reduced medicine prices, while 75 percent note consistent availability of essential medicines.
“Our focus remains on supporting high-impact businesses that improve essential services for everyday people,” said Jacob Kholi, Chief Executive and Investment Officer of GIP Ghana. “Strengthening mPharma’s footprint in Francophone West Africa will help more communities access affordable medicines while reinforcing the resilience of regional healthcare systems.”
Strengthening Regional Health Systems
mPharma’s integrated healthcare services include mutti Doctor, which provides virtual medical consultations and community screenings. The company also runs targeted programmes in chronic disease management, women’s health and children’s care. Its Diabetes Test & Treat initiative has recorded optimal blood sugar control in 80 percent of patients within six months.
“With GIP’s support, we can continue enhancing partnerships with pharmacies and healthcare providers to improve patient care and ensure equitable access to quality medicines across Ghana, Francophone West Africa and the wider region,” said Kwesi Arhin, Chief Executive Officer of mPharma.
Investor Confidence in Scaling Healthcare Innovation
BII, which has supported mPharma in earlier investment rounds, says the new capital confirms confidence in the company’s scalable business model.
“We have seen firsthand mPharma’s impact in improving access to affordable medicines,” said Kwabena Asante-Poku, BII Country Director for Ghana. “This new partnership will accelerate expansion in Francophone West Africa and strengthen health service delivery in more communities.”
With cost pressures, medicine availability concerns and chronic disease rates rising across West Africa, analysts say mPharma’s expansion model could play a defining role in reshaping the region’s primary healthcare landscape.
